Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.0852W HIGH $4.58
Volume
435.06 K
Value Traded
1.62 M
Short % Float
4.93%
-3.87%Week
+10.03%1 Month
-12.95%3 Month
+21.9%6 Month
-63.24%5 Year
+69.88%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
257.25 M
EPS (TTM)
-0.71
P/E Ratio
-
Ent. Value
96.67 M
Total Shares
68.97 M
Float Shares
64.41 M
Insiders
6.61%
Institutions
86.01%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
OSUR Catalyst Timeline
Dated clinical, regulatory and corporate events for OraSure Technologies, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for OraSure Technologies, Inc.
781Total events
2Upcoming
181Tier-1 (high impact)
2009 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Emergency Use AuthorizationFDA Decision
FDA Emergency Use Authorization for OraQuick™ Ebola 2.0 Rapid Antigen Test
Ebola diseasesource ↗
▼IND WithdrawalIND
Withdrawal of current submission for InteliQuick™ CT/NG molecular self-test
Chlamydia trachomatis and Neisseria gonorrhoeaesource ↗
▲FDA ApprovalFDA Decision
FDA clearance of Colli-Pee™•Dx Urine Collection Kit for use with Roche's tests
Sexually transmitted infections (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium)source ↗
▲FDA ApprovalColli-Pee™•DxApprovedFDA Decision
FDA clearance of Colli-Pee™•Dx Urine Collection Kit
Sexually transmitted infections (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium)source ↗
◆PDUFA DateRegulatory Filing
FDA review underway for Sherlock CT/NG test
Chlamydia and gonorrhea (CT/NG)source ↗
●NDA SubmissionRegulatory Filing
Submitted CT NG molecular self-test for FDA clearance
Chlamydia trachomatis and Neisseria gonorrhoeaesource ↗
●NDA SubmissionColli-Pee®FiledRegulatory Filing
Submitted Colli-Pee at-home urine collection device for FDA clearance
sexually transmitted infections (STIs)source ↗
◆Timing GuidancePresentation
CT/NG self-test expected to be submitted to FDA
Chlamydia Trachomatis and Neisseria Gonorrhoeaesource ↗
●Timing GuidanceCT/NGPresentation
Plans to submit CT/NG test to FDA by end of 2025
Chlamydia and gonorrheasource ↗
◆Timing GuidancePresentation
Anticipated FDA submission for Sherlock rapid molecular self-test for CT/NG
Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG)source ↗
◆Timing GuidanceColli-Pee®FiledPresentation
Anticipated FDA submission for Colli-Pee at-home urine collection device
◆Product LaunchPost-Market
Launch of HEMAcollect PROTEIN blood collection tube for research use
●NDA SubmissionRegulatory Filing
Submitted application for CT/NG rapid molecular self-test
Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG)source ↗
●NDA SubmissionColli-Pee®FiledRegulatory Filing
Submitted application for Colli-Pee™ at-home urine collection device
sexually transmitted infections (STIs)source ↗
●FDA Filing AcceptedRegulatory Filing
FDA submission for at-home first-void urine self-collection
◆FDA Feedback ReceivedFDA Meeting
Regulatory review underway for at-home first-void urine self-collection following FDA submission
●FDA Filing AcceptedRegulatory Filing
FDA submission for Sherlock CT/NG Molecular Self-test
Chlamydia and gonorrhea (CT/NG)source ↗
◆Timing GuidancePresentation
Sherlock CT/NG self-test expected to be submitted to FDA
Chlamydia Trachomatis and Neisseria Gonorrhoeaesource ↗
◆Oral PresentationPresentation
OraSure to participate in Stephens Annual Investment Conference with Q&A session
●Manufacturing MilestoneCMC / Inspection
Insource production of certain sample management products into Bethlehem facility over next 18 months
●Quarterly UpdateCorporate
Company guided Q4 2025 total revenues of $25 million to $28 million
◆NDA SubmissionRegulatory Filing
Submission to FDA for at-home first-void urine self-collection for multiple STIs
multiple STIssource ↗
▲Product LaunchHEMAcollect™●PROTEINPost-Market
Launch of HEMAcollect™●PROTEIN blood collection tube for proteomic research
▲Product LaunchPost-Market
Protein-specific blood collection & sample stabilization RUO launched
▲Product LaunchHEMAcollect™●PROTEINPost-Market
Launched HEMAcollect PROTEIN blood collection device for proteomic research
▲Product LaunchColli-Pee®FiledPost-Market
New York State Department of Health approved at-home cervical cancer risk screening test using Colli-Pee™
cervical cancer risk screeningsource ↗
▲Partnership / LicenseCorporate
Renewed customer agreement with Myriad Genetics for Oragene™ Dx saliva collection kits
●Program DiscontinuationCorporate
Divested certain assets related to Risk Assessment testing product line
▲Product LaunchPost-Market
Planned launch of new sample management solution for blood proteomics
blood proteomicssource ↗
●Program DiscontinuationCorporate
Expected to complete exit from Risk Assessment testing business in Q2
●Quarterly UpdateCorporate
Company anticipates COVID-19 and Risk Assessment testing revenues of approximately $0.5 million in Q2 2025
Past FDA Catalysts and PDUFA Decisions
How OSUR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D21 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 94%
Micro Cap(rank 619 of 658)
Percentile Rank
OraSure Technologies, Inc. faces pipeline headwinds (21/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every OSUR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Boyd Steven KyleDirector | Grant/Award | 3,666 163,234 held | $4.43 | 06/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OSUR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.3 % (-88.9 %) | 2.14 M | 565.00 K | -81.51% ( -2.49 M) |
OSUR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OSUR ranks across every disease it competes in
Competitive Position is a premium feature
See how OSUR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOSUR News
OSUROraSure Announces Second Quarter 2026 Financial Results
OraSure Technologies reported its Q2 2026 financial results, showing a 9.7% sequential revenue increase to $30.6 million. The company achieved FDA clearance for its Colli-Pee™•Dx urine collection device and received Emergency Use Authorization for the OraQuick™ Ebola 2.0 Rapid Antigen Test. Despite these advancements, total revenues decreased by 2% year-over-year, and the company recorded a non-GAAP operating loss.
Read more →OSUR▲ +6.3%on this news
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
OraSure Technologies, Inc. will announce its second quarter 2026 financial results on August 5, 2026, after market close. The company will host a conference call at 5 p.m. Eastern Time to discuss these results. A webcast of the call will be available on their investor relations page and archived for one year.
Read more →OSUROraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
OraSure Technologies has received FDA clearance for its Colli-Pee™•Dx Urine Collection Kit, enabling at-home self-collection for STI testing. This advancement allows for convenient sample collection while maintaining sample integrity. The kit supports Roche's molecular diagnostic systems and aims to improve access for underserved populations, facilitating scalable testing and public health initiatives.
Read more →OSUROraSure Announces First Quarter 2026 Financial Results
OraSure Technologies, Inc. reported a revenue of $27.9 million for Q1 2026, surpassing its guidance midpoint. The company highlighted gross margin expansion and a strong balance sheet, which positions it well for growth and potential acquisitions. OraSure aims to decentralize diagnostics to improve healthcare accessibility and affordability.
Read more →OSUROraSure Technologies, Inc. 2OTI Proprietary Disclaimers Forward-Looking Statements: This presentation of OraSure Technologies, Inc. (the "Company" or "OraSure") contains certain "forward-looking statements" within the me
OraSure Technologies, Inc. has provided an investor update discussing its transformation strategy and financial performance. In Q1, the company reported a 4% growth in total revenue, demonstrating positive traction in its core business segments. The update highlights key operational improvements, including a focus on disciplined execution and the return to breakeven for its core business. Additionally, there is an optimistic outlook for growth driven by innovation and improved visibility into funding for critical testing programs.
Read more →OSUROraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
OraSure Technologies, Inc. will announce its first quarter 2026 financial results during an earnings call scheduled for May 6, 2026. The call will take place at 5 p.m. ET and will be accessible via a webcast on the company's investor relations page. This event is part of OraSure's commitment to transparency and stakeholder engagement.
Read more →OSUROraSure Technologies Appoints John D. Bertrand to its Board of Directors
OraSure Technologies has appointed John D. Bertrand as an independent director to its Board of Directors. His extensive experience in healthcare technology and AI-enabled diagnostics is expected to bolster the company's strategic initiatives. Additionally, OraSure plans to seek shareholder approval to declassify its Board at the upcoming 2026 Annual Meeting, reflecting its commitment to governance and shareholder engagement.
Read more →OSURStrategy & Growth Outlook OraSure is executing a focused strategy with near-term catalysts expected to drive revenue growth, margin expansion, and profitability Public health funding environment stabilizing across U.S. a
OraSure is actively pursuing a focused strategy designed to enhance revenue growth and profitability, with several product launches on the horizon. The company's diagnostics segment is poised for expansion, leveraging existing infrastructures and improving efficiency through operational transitions. Despite facing challenges, including pressure from Altai Capital regarding board decisions, OraSure aims for a strong market position as health funding stabilizes and testing volumes recover post-2025.
Read more →OSUROraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
OraSure Technologies, Inc. is responding to Altai Capital's demands for board representation, emphasizing its commitment to shareholder value and upcoming milestones in 2026. The company has engaged extensively with Altai but has faced rejection of settlement proposals. OraSure's Board has been refreshed with new independent directors to guide the company through this critical phase.
Read more →OSUR▲ +10%on this news
OraSure Announces Fourth Quarter 2025 Financial Results
OraSure Technologies reported its Q4 2025 financial results, achieving revenue of $26.8 million, which surpassed expectations. The company is optimistic about growth in 2026, driven by anticipated regulatory clearances and new product launches. OraSure's CEO highlighted the stability in key segments and the company's strategic investments to enhance value.
Read more →OSUROraSure to Launch OraQuick™ HIV Self-Test in Canada
OraSure Technologies has announced that its OraQuick HIV Self-Test has received licensing from Health Canada, making it the first oral HIV self-test available in Canada. The test allows individuals to determine their HIV status using a simple oral swab in just 20 minutes. This initiative aims to improve access to HIV testing and support public health efforts in combating the epidemic.
Read more →OSUROraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
OraSure Technologies, Inc. will hold its earnings conference call on February 25, 2026, at 5 p.m. ET to discuss its fourth quarter 2025 financial results and business developments. The call will be accessible via a webcast on the company's investor relations page, which will also archive the session afterward.
Read more →OSUROraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
OraSure Technologies has confirmed the receipt of director nominations from Altai Capital for the upcoming 2026 Annual Meeting of Stockholders. The nominations include Altai's founder, Rishi Bajaj. However, since interviewing Mr. Bajaj, OraSure's Board has appointed alternative candidates and has not engaged further with Altai. The Board has seen a significant refreshment with seven departures and three new independent members, aiming to enhance its oversight of growth and value creation.
Read more →OSUROraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
OraSure Technologies has submitted applications to the FDA for a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae, alongside its Colli-Pee™ urine collection device. These submissions aim to enhance accessibility and convenience in STI testing. The company anticipates significant market opportunities, although regulatory approvals and competition pose potential risks.
Read more →OSUROraSure Submits CT NG Molecular Self-Test and Colli-Pee Urine Collection Device for FDA Review
OraSure Technologies has submitted applications for FDA clearance of two new products: a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae, and an at-home urine collection device called Colli-Pee. The rapid test aims to decentralize diagnostics by providing near-instant results in a convenient format. Additionally, the Colli-Pee device targets patients' preferences for private testing. These submissions are part of OraSure's strategy to expand its market presence and improve access to STI testing.
Read more →OSUROraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates
OraSure Technologies has confirmed the intent of Altai Capital to nominate two candidates for election to its Board of Directors at the 2026 Annual Meeting. The company maintains a commitment to shareholder value and has engaged in dialogue with Altai, evaluating its founder, Rishi Bajaj, for board service. Despite not appointing him, OraSure has made efforts to enhance its Board and is actively pursuing innovation in diagnostics. The company remains well-positioned financially with substantial cash reserves and no debt as it strives for sustainable profitability.
Read more →OSUROraSure to Participate in Upcoming Investor Conference
OraSure Technologies, Inc. (NASDAQ: OSUR) has announced its participation in the upcoming Stephens Annual Investment Conference on November 19, which includes a Q&A session at 10 a.m. CT. The company will provide a live webcast and replay of the session on their investor relations website. OraSure focuses on decentralizing diagnostics, innovating in health technology, and improving access to healthcare through various products. This initiative indicates their commitment to maintaining transparent communication with shareholders and the market.
Read more →OSUR▼ -6.6%on this news
OraSure Announces Third Quarter 2025 Financial Results
OraSure Technologies reported a revenue of $27.1 million for Q3 2025, with optimism for growth in 2026 driven by diversification and new product launches. CEO Carrie Eglinton Manner emphasized the company's strategy to decentralize diagnostics and improve healthcare access. The company anticipates Q4 revenues between $25 million and $28 million, with minimal contributions from COVID-19 testing.
Read more →About OraSure Technologies, Inc.
Headquarters220 E FIRST ST, BETHLEHEM, PA, 18015
BIOPHARMAWATCH ELITE PLUS
Trade the next OSUR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime